Annapolis, MD, United States of America

Clare E Gutteridge


Average Co-Inventor Count = 4.8

ph-index = 4

Forward Citations = 52(Granted Patents)


Location History:

  • Westfield, NJ (US) (2002 - 2003)
  • Dover, NH (US) (2005)
  • Annapolis, MD (US) (2006)

Company Filing History:


Years Active: 2002-2006

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Clare E Gutteridge: Innovator in Therapeutic Compounds

Introduction

Clare E Gutteridge is a prominent inventor based in Annapolis, MD (US). She has made significant contributions to the field of therapeutic compounds, particularly in the treatment of dyslipidemic conditions. With a total of 4 patents to her name, Gutteridge's work has the potential to impact many lives.

Latest Patents

One of her latest patents focuses on therapeutic compounds for treating dyslipidemic conditions. This invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters, and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol. Another patent also addresses therapeutic compounds for treating dyslipidemic conditions, specifically compounds of Formula I and the pharmaceutically acceptable salts and esters thereof, wherein Z is selected from a specific group.

Career Highlights

Clare E Gutteridge is currently associated with Merck & Company, Inc., a leading global healthcare company. Her work at Merck has allowed her to focus on innovative solutions in the pharmaceutical industry, contributing to advancements in medical treatments.

Collaborations

Throughout her career, Gutteridge has collaborated with notable colleagues, including A Brian Jones and Alan D Adams. These collaborations have fostered a productive environment for innovation and research.

Conclusion

Clare E Gutteridge's contributions to the field of therapeutic compounds exemplify her dedication to improving health outcomes. Her innovative patents and collaborations highlight her role as a key figure in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…